NEU: I doubt that there will be a CR Kevi. Latest 4C showed 11.4m in cash plus the US Army is funding $23m for clinical trials. I suspect this is just a retrace after the stock more than doubled. I'll be buying back around 2.4 cents.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
